Dosage of Betnitek in details
Management of Chronic Asthma: Adults and Children >12 years: 100-400 mcg twice daily. Maximum: 1000 mcg twice daily.
Children (5-12 years): 100-200 mcg twice daily. Maximum: 200-400 mcg twice daily.
Prophylaxis of Asthma: Adults and Children >12 years: 50-200 mcg twice daily. Increase if necessary to maximum 400 mcg twice daily.
Children (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses.
When patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.
Therapy in New Patients: Mild Asthma: 50-100 mcg twice daily.
Moderate Asthma: 100-200 mcg twice daily.
Severe Asthma: 200-400 mcg twice daily.
When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially Betnitek 100 mcg puff should be prescribed for beclometasone dipropionate (CFC) or budesonide 200-250 mcg; fluticasone propionate 100 mcg.
When switching a patient with poorly-controlled asthma from another corticosteroid inhaler, initially Betnitek 100 mcg puff should be prescribed for beclometasone dipropionate (CFC) or budesonide or fluticasone propionate 100 mcg. The dose of Betnitek should be adjusted to response.
Use in the elderly or patients with hepatic or renal impairment: There are no special dosage recommendations for use in the elderly or in patients with hepatic or renal impairment.
What other drugs will affect Betnitek?
There may be other drugs that can interact with beclomethasone. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Betnitek interactions
Due to the very low plasma concentration achieved after inhaled dosing, clinically significant drug interactions are in general unlikely. Care should be taken when co-administering with known strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nelfinavir, ritonavir) as there is a potential for increased systemic exposure to beclometasone.
Reviews
The results of a survey conducted on ndrugs.com for Betnitek are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Betnitek. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
